The Evaluation of the Efficacy and Safety of Oral Colchicine in the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trails

Table 1

Basic characteristics of included studies.

Author; year	LEO	at baseline	Female (%)		Grade of OA	Dose	Primary outcome measures	Adverse events ()	Follow-up (month)
Amirpour et al. 2016 [20]	I	81	98		Not mentioned	0.5 mg/bid	VAS; modified WOMAC index	C: 2; P: 5	4
Aran et al. 2011 [19]	I	61	100		Primary OA	0.5 mg/bid	Patients’ global assessment; physician’s global assessment (recorded on VAS)	C: 1; P: 0	3
Das et al. 2002^‡ [18]	I	36	77.8		Moderately severe symptomatic OA	0.5 mg/bid	Index knee pain (VAS); total WOMAC scores.	C: 11; P: 4	5
Das et al. 2002^† [12]	I	39	66.7		Not mentioned	0.5 mg/bid	Vas pain; Total KGMC scale (modified WOMAC index suit for India)	C: 33; P: 47	5
Leung et al. 2018 [21]	I	109	70.7		0-IV (KL grade)	0.5 mg/bid	Total WOMAC score; improvement in pain (VAs);	C: 95; P: 67	4

LOE: level of evidence; : number; SD: standard deviation; NA: not applicable; OA: osteoarthritis; KL: Kellgren and Lawrence grading system; WOMAC: Western Ontario and McMaster University Osteoarthritis Index; VAS: visual analog scale; C: colchicine group; P: placebo group.